Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB01
- Development stage
- Phase 1
- Lead developer
- Johnson & Johnson
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
BB01 is a live, attenuated oral vaccine candidate developed by Berna Biotech (now part of Janssen/Johnson & Johnson) for the prevention of enterotoxigenic *Escherichia coli* (ETEC) infection, a primary cause of travelers' diarrhea. The vaccine consists of attenuated bacterial strains engineered to express key ETEC colonization factor antigens (CFAs) and coli surface (CS) antigens. Upon oral administration, BB01 is designed to temporarily colonize the small intestine and elicit a protective mucosal and systemic immune response against the surface antigens that ETEC uses to adhere to the intestinal wall. It has been evaluated in Phase I clinical trials to assess safety and immunogenicity in healthy adults.
02
Targets
CS (Coli surface antigen)SLAMF7 (Signaling lymphocytic activation molecule family member 7)
Beyond the preview
Go deeper on BB01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BB01.